首页> 外文OA文献 >Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

【2h】

Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy

机译：JUNIPER研究的治疗依据和研究设计：接受最佳支持治疗的Abemaciclib与依洛罗替尼进行最佳支持治疗的IV期随机研究，针对IV期非小细胞肺癌，可检出KRAS突变的患者，其铂类疾病已进展基于化学疗法

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Goldman Jonathan W.; Shi Peipei; Reck Martin; Paz-Ares Luis; Koustenis Andrew; Hurt Karla C.;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy [J] . Goldman Jonathan W., Shi Peipei, Reck Martin, Clinical lung cancer . 2016,第1期

机译：JUNIPER研究的治疗原理和研究设计：接受最佳支持治疗的Abemaciclib与依洛罗替尼进行最佳支持治疗的IV期随机临床试验，该研究针对IV级非小细胞肺癌，可检出KRAS突变的患者，其铂类药物已进展基于化学疗法
2. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer [J] . Spigel David R., Edelman Martin J., Mok Tony, Clinical lung cancer . 2012,第6期

机译：MetLung试验的治疗原理研究设计：Onartuzumab（MetMAb）联合厄洛替尼与单独使用厄洛替尼的随机，双盲III期研究在已接受IIIB或IV期Met阳性非小细胞化疗的患者中肺癌
3. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer [J] . Luis G Paz-Ares, Sedat Altug, Alexandra Thareau Vaury, BMC Cancer . 2010,第1期

机译：培美曲塞加顺铂诱导治疗晚期非鳞状非小细胞肺癌后立即进行培美曲塞加最佳支持治疗与最佳支持治疗的III期，双盲，安慰剂对照研究的治疗原理和研究设计
4. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
5. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER [O] . Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, 2020

机译：患有阶段非小细胞肺癌患者ABEMACICLIB与牛油蛋白的随机阶段III研究其失败的KRAS突变失败的基于铂类治疗：杜松
6. Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer [O] . Luis G Paz-Ares, Sedat Altug, Alexandra Thareau Vaury, 2010

机译：培美曲塞加顺铂治疗晚期非鳞状非小细胞肺癌后立即进行培美曲塞加最佳支持治疗与最佳支持治疗的III期，双盲，安慰剂对照研究的治疗原理和研究设计

著录项

相似文献

相关主题

期刊订阅